Bain / Vitabiotics

A billion-dollar brand almost nobody outside Britain has heard of. This is the deal that made me rethink the whole framework.

The third model

Thorne won on what a clinician will vouch for. Nestlé’s mainstream brands won on shelf economics. Vitabiotics did neither, and it is bigger than I expected.

It won by owning specific-need aisles outright. Pregnancy. Men’s. Women’s. Hair and skin. Bone. These are shelves where the shopper arrives with exactly one question and wants exactly one answer. Ask a British pharmacist for a pregnancy multivitamin and you will get a brand name, not a comparison. Being that name for fifty-five years is a moat, and it is a cheaper moat than Thorne’s.

What Bain is actually underwriting

Bain’s Asian private equity team led this, and the perimeter deliberately includes Meyer Organics in India and the Egyptian business. That is not a UK consolidation thesis. That is: take a brand system already proven in one country and run it through markets where the specific-need habit is forming right now.

Where I would push

• Specific-need aisles are exactly where private label attacks first, because the shopper already knows what they want.
• A founder-led company of this age carries commercial relationships that live in people, not contracts.
• The India and Africa thesis needs regulatory patience, which sponsors do not always have.

My call

The most interesting of the five and the least written about, which is usually a good sign. Without revenue I cannot tell you if the price is right. I can tell you the question that settles it: does being the default answer travel across a border, or is it built one pharmacist at a time?

Sources

• Bloomberg, reported valuation.
• Business Standard, group perimeter.